drugset / Trial / NCT03068234
Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is to evaluate the efficacy and safety of an antifibrotic agent, pirfenidone as treatment of systemic sclerosis. The primary outcome of this study is improvement of skin fibrosis.
Timeline
- Start
- 2017-05
- Primary completion
- 2019-04
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirfenidone | Small molecule | 200 mg | Oral |